These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23826758)

  • 21. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?
    Kanavos P; Taylor D
    Curr Med Res Opin; 2007 Oct; 23(10):2467-76. PubMed ID: 17764613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority.
    Ali GK; Yahia Y
    East Mediterr Health J; 2012 Aug; 18(8):811-20. PubMed ID: 23057369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discounts and rebates granted to public payers for medicines in European countries.
    Vogler S; Zimmermann N; Habl C; Piessnegger J; Bucsics A
    South Med Rev; 2012 Jul; 5(1):38-46. PubMed ID: 23093898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflated medicine prices in Vietnam: a qualitative study.
    Nguyen TA; Knight R; Mant A; Razee H; Brooks G; Dang TH; Roughead EE
    Health Policy Plan; 2017 Jun; 32(5):647-656. PubMed ID: 28453716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyzstan.
    Waning B; Maddix J; Soucy L
    BMC Health Serv Res; 2010 Jul; 10():205. PubMed ID: 20626904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China.
    Yang H; Dib HH; Zhu M; Qi G; Zhang X
    Health Policy Plan; 2010 May; 25(3):219-29. PubMed ID: 19955093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List.
    Gotham D; Barber MJ; Hill AM
    BMJ Open; 2019 Sep; 9(9):e027780. PubMed ID: 31575568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Cardiovascular Medicines Prices in Four European Countries.
    Mitkova Z; Vasileva M; Savova A; Manova M; Terezova S; Petrova G
    Front Public Health; 2020; 8():433. PubMed ID: 32974262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The French medecine pricing committee].
    Giorgi D
    Ann Pharm Fr; 2017 Sep; 75(5):373-384. PubMed ID: 28583317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prices & availability of common medicines at six sites in India using a standard methodology.
    Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
    Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generic Medicine Pricing Policies in Europe: Current Status and Impact.
    Dylst P; Simoens S
    Pharmaceuticals (Basel); 2010 Mar; 3(3):471-481. PubMed ID: 27713264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
    PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
    Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
    Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
    [No Abstract]   [Full Text] [Related]  

  • 36. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India.
    Satheesh G; Sharma A; Puthean S; Ansil T P M; E J; Raj Mishra S; Unnikrishnan MK
    Trop Med Int Health; 2020 Dec; 25(12):1467-1479. PubMed ID: 32959441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability and affordability of antimalarial and antibiotic medicines in Malawi.
    Khuluza F; Heide L
    PLoS One; 2017; 12(4):e0175399. PubMed ID: 28419126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria.
    Orubu ESF; Robert FO; Samuel M; Megbule D
    Health Policy Plan; 2019 Dec; 34(Supplement_3):iii20-iii26. PubMed ID: 31816074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.